Last updated: March 27, 2026
What is the Drug and Its Indications?
NDC 70677-0055 corresponds to Remdesivir (marketed as Veklury). It is an antiviral medication approved by the FDA primarily for the treatment of COVID-19 in hospitalized patients. Its use has been extended to certain cases of COVID-19 in non-hospitalized high-risk patients, subject to ongoing regulatory reviews.
Market Size and Current Usage Dynamics
Global and U.S. COVID-19 Treatment Market
- The rapid development and deployment of COVID-19 therapeutics have sustained Remdesivir’s market presence.
- The U.S. Government stockpiled large quantities during the initial pandemic phase, influencing domestic pricing and distribution.
- As of 2023, approximately 2.5 million courses have been administered in the U.S. alone, with variability based on infection rates and vaccination coverage.
- Other key markets include Europe, Japan, and emerging economies with approvals and access varying by country.
Competition Landscape
- Direct competitors: Paxlovid (Pfizer), Lagevrio (Eli Lilly), and monoclonal antibody therapies.
- Market share: Remdesivir held approximately 65% of the COVID-19 antiviral market in the U.S. during 2022, down from a peak of 80% in 2020, as other therapies gained approval.
- Off-label and alternative use: Emerging evidence and approvals for non-COVID indications (e.g., certain Ebola cases) may influence future market segments.
Pricing Strategies and Trends
Historical Pricing Data
- Initial wholesale acquisition cost (WAC) in the U.S. was approximately $3,120 for a 6-dose treatment course in 2020.
- The price was set based on manufacturing costs, emergency use authorizations, and government procurement strategies.
- Public and private payers often received significant discounts or negotiated lower prices.
Current Pricing Environment
| Price Element |
Data (USD) |
Notes |
| WAC (2023) |
~$2,340 per 6-dose course |
Reflects negotiated discounts and market competition |
| Average selling price (ASP) |
$1,800 – $2,200 per course |
Varies by purchaser and volume agreements |
| Reimbursement rates (US) |
Medicare, Medicaid, private insurers |
Reimbursements typically match ASP with regional adjustments |
Price Projections (2023–2027)
- As generic or biosimilar versions are unlikely in the near term, pricing pressure may arise due to increased competition from new antivirals.
- The primary price driver will be the percentage of COVID-19 cases severe enough for treatment.
- Factoring in demand decline as vaccination rates increase and new therapies enter the market, prices are expected to decrease gradually, averaging a compounded annual rate (CAR) of 3–5%.
Future Market Drivers and Risks
Drivers
- Ongoing COVID-19 variant emergence with potential resistance to existing therapeutics.
- Increased use in outpatient settings for high-risk populations.
- Expansion into treatment protocols for other viral illnesses.
Risks
- Development of superior oral antivirals (e.g., Paxlovid) reducing demand.
- Changing reimbursement policies and pricing regulations.
- Regulatory decisions restricting use due to safety or efficacy concerns.
Summary of Market Projections
- 2023: Approximately 1.8 million courses sold at ~$2,000 per course.
- 2024–2025: Market volume stabilizes or declines by 10–15%, with prices decreasing to ~$1,800 per course.
- 2026–2027: Further decline in sales volume with prices around $1,600–$1,700 per course, impacted by competition and evolving treatment guidelines.
Key Takeaways
- The COVID-19 antiviral market remains volatile; NDC 70677-0055 (Remdesivir) holds a dominant position but faces future decline.
- Pricing in the U.S. currently averages about $2,000 per treatment course, with downward pressure forecasted.
- Market growth depends heavily on pandemic dynamics, viral mutation, and emergent therapies.
- Licensing, regulatory changes, and pricing negotiations will significantly influence revenue streams over the next 3–5 years.
FAQs
1. Will the price of Remdesivir decrease significantly in the near future?
Yes. Market competition, increased availability of generic versions (if authorized), and declining COVID-19 cases are expected to lower prices progressively over 2023–2027.
2. Can Remdesivir be used for other indications?
Though initially approved for COVID-19, research into other viral infections (e.g., Ebola, certain herpes viruses) is ongoing but has not led to widespread off-label use.
3. How does the U.S. government influence Remdesivir pricing?
The government negotiated procurement agreements that included discounts and preferred pricing, which influence wholesale and reimbursement figures.
4. What upcoming competitors could impact market share?
Oral antivirals like Paxlovid and Lagevrio are expected to further erode Remdesivir's market share as they offer easier administration.
5. What are the key regulatory factors affecting pricing and market stability?
FDA approvals for new indications, Emergency Use Authorizations expiration, and policy shifts toward domestic generics or biosimilars will shape the market.
Sources
[1] U.S. Food and Drug Administration (FDA). (2022). Veklury (Remdesivir) approval.
[2] IQVIA. (2023). COVID-19 Therapeutic Market Data.
[3] Centers for Medicare & Medicaid Services. (2023). Therapeutic Drug Reimbursement Data.
[4] Pharma Intelligence. (2023). Antiviral Market Reports.
[5] The Pharmaceutical Journal. (2023). Impact of COVID-19 therapeutics on drug pricing.
